29 July 2023
Researchers at the 59th Medical Wing of the Air Force have tested a new silica-based hemostatic matrix (HM) designed to stop severe bleeding from traumatic injuries. The innovation, tested alongside the current military standard QuikClot Combat Gauze® (QCG), demonstrated comparable effectiveness in a preclinical study using a severe arterial injury model.
Study Design
Using a controlled injury model, the study tested the HM and QCG on severe femoral artery injuries in anesthetized swine. After a 45-second period of free bleeding, each wound was treated with either HM or QCG. The researchers then monitored survival rates, blood loss, hemostasis (the ability to stop bleeding), and artery function over a 60-minute observation period.
Key Findings
Survival Rates: Both HM and QCG groups showed high survival rates (80% and 90%, respectively).
Bleeding Control: Immediate bleeding control was achieved in 50% of HM-treated cases and 40% of QCG cases.
Safety: Unlike QCG, no evidence of arterial damage (contrast extravasation) was observed with HM-treated wounds.
Heat Safety: Neither product caused dangerous exothermic (heat-releasing) reactions during application.
Next Steps
With continued testing and refinement, SiOxMed’s hemostatic matrix could play a pivotal role in transforming how life-threatening bleeding is managed. As the next milestone in its development, SiOxMed is preparing to pursue FDA 510(k) clearance for hemostatic indications.
About SiOxMed
SiOxMed is dedicated to advancing medical innovation through cutting-edge solutions for wound care and hemostasis. By collaborating with researchers, clinicians, and industry leaders, SiOxMed is shaping the future of trauma medicine.
Angus AA, July LN, McCarthy PM, Shepard ND, Rall JM, Radowsky JS. Testing and Evaluation of a Novel Hemostatic Matrix in a Swine Junctional Hemorrhage Model. J Surg Res. 2023 Nov;291:452-458. doi: 10.1016/j.jss.2023.06.040. Epub 2023 Jul 29. PMID: 37523895.
Learn more
